Prudential-Bache Securities’ R&D; Funding Corp. subsidiary has...

Prudential-Bache Securities’ R&D; Funding Corp. subsidiary has pumped an additional $1.3 million into Synbiotics Corp., increasing its interest in the San Diego-based monoclonal antibody company to $9.8 million. Synbiotics, which is using the original investment to develop 11 veterinary products, will use the $1.3 million to develop an additional veterinary product.